A share price of Ovid Therapeutics Inc [OVID] is currently trading at $1.75, up 10.76%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The OVID shares have gain 4.79% over the last week, with a monthly amount glided 36.72%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ovid Therapeutics Inc [NASDAQ: OVID] stock has seen the most recent analyst activity on October 09, 2025, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $7. On June 18, 2024, downgrade downgraded it’s rating to Perform. B. Riley Securities started tracking the stock assigning a Buy rating and suggested a price target of $9 on April 30, 2024. H.C. Wainwright initiated its recommendation with a Buy and recommended $9 as its price target on April 29, 2024. Wedbush started tracking with a Outperform rating for this stock on April 05, 2024, and assigned it a price target of $8. In a note dated December 21, 2023, BTIG Research initiated an Buy rating and provided a target price of $11 on this stock.
Ovid Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $0.24 and $2.01. Currently, Wall Street analysts expect the stock to reach $7.33 within the next 12 months. Ovid Therapeutics Inc [NASDAQ: OVID] shares were valued at $1.75 at the most recent close of the market. An investor can expect a potential return of 318.86% based on the average OVID price forecast.
Analyzing the OVID fundamentals
Trailing Twelve Months sales for Ovid Therapeutics Inc [NASDAQ:OVID] were 6.65M which represents 3611.24% growth. Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at -6.25%, Pretax Profit Margin comes in at -5.74%, and Net Profit Margin reading is -5.74%. To continue investigating profitability, this company’s Return on Assets is posted at -0.49, Equity is -0.59 and Total Capital is -0.61. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Ovid Therapeutics Inc [NASDAQ:OVID] is 4.72. Further, the Quick Ratio stands at 4.72, while the Cash Ratio is 3.18. Considering the valuation of this stock, the price to sales ratio is 18.71, the price to book ratio is 2.23.
Transactions by insiders
Recent insider trading involved ALEXANDER MARGARET A., President and COO, that happened on Feb 26 ’25 when 5279.0 shares were sold. CBFO, Rona Jeffrey A completed a deal on Feb 26 ’25 to sell 3902.0 shares. Meanwhile, President and COO ALEXANDER MARGARET A. bought 6810.0 shares on Jan 27 ’25.
